Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer
The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Audrey Sternberg Source Type: news
Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Michael J. Morris, MD Source Type: news
Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news
Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial
The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Neal D. Shore, MD, FACS Source Type: news
Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Andres Poveda, MD Source Type: news
Zsofia K. Stadler, MD, on the Importance of Germline Analyses in Advanced Cancer
Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Zsofia K. Stadler, MD Source Type: news
Thomas Powles, MD, PhD on Next Steps for Avelumab and the Future of Treatment for Urothelial Cancer
The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Thomas Powles, MD, PhD Source Type: news
Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news
Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Roy S. Herbst, MD, PhD Source Type: news
Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news
Rana R. McKay, MD, on the Impact of the Phase II OMNIVORE Trial
The expert from the University of California San Diego discusses the importance of the findings presented at the 2020 ASCO Virtual Scientific Program (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Rana R. Mckay, MD Source Type: news
ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Ajay K. Nooka, MD Source Type: news
John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study
Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL). (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: John Kuruvilla, MD Source Type: news
Clinical Implications from the TAILORx Trial
Jane L. Meisel, MD, discusses the clinical implications of the TAILORx trial and how it has affected practice. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Matthew Steven Davids, MD, MMSc, on Venetoclax Plus R-EPOCH to Treat Richter ’s Syndrome
The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter ’s Syndrome. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Matthew Steven Davids, MD, MMSc Source Type: news
